Zacks Research Has Negative Estimate for PCRX Q1 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Investment analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of Pacira BioSciences in a research note issued on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.60 for the quarter, down from their previous forecast of $0.61. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q3 2025 earnings at $0.54 EPS and Q2 2026 earnings at $0.63 EPS.

A number of other equities research analysts also recently issued reports on the stock. Jefferies Financial Group upped their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Royal Bank of Canada lifted their price target on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Barclays decreased their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Pacira BioSciences in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $23.50.

Pacira BioSciences Stock Up 0.3 %

NASDAQ PCRX opened at $19.86 on Friday. The stock has a 50 day moving average price of $17.21 and a 200-day moving average price of $19.18. Pacira BioSciences has a one year low of $11.16 and a one year high of $35.95. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company has a market capitalization of $916.94 million, a P/E ratio of -9.78 and a beta of 0.80.

Institutional Trading of Pacira BioSciences

Large investors have recently made changes to their positions in the stock. Innealta Capital LLC bought a new stake in Pacira BioSciences during the 2nd quarter valued at about $50,000. nVerses Capital LLC raised its stake in shares of Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after acquiring an additional 1,600 shares in the last quarter. CWM LLC boosted its holdings in shares of Pacira BioSciences by 713.6% in the third quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after purchasing an additional 5,716 shares during the period. Virtus Investment Advisers Inc. purchased a new stake in shares of Pacira BioSciences in the third quarter valued at approximately $98,000. Finally, Quest Partners LLC bought a new position in Pacira BioSciences in the second quarter worth approximately $113,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.